Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vinblastine is a vinca alkaloid antineoplastic agent isolated from the periwinkle plant (Catharanthus roseus). It works by binding to tubulin, thereby inhibiting the assembly of microtubules and disrupting the mitotic spindle formation. This leads to M phase-specific cell cycle arrest and eventual cell death. At low concentrations, it suppresses microtubule dynamics, while at higher concentrations, it reduces microtubule polymer mass. Vinblastine is used to treat various cancers including Hodgkin's lymphoma, non-Hodgkin's lymphoma, breast cancer, testicular cancer, bladder cancer, and other conditions like histiocytosis and Kaposi's sarcoma.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on vinblastine.